Cargando…

Norepinephrine use in cardiogenic shock patients is associated with increased 30 day mortality

AIMS: Norepinephrine is recommended as a first‐line vasopressor agent in the haemodynamic stabilization of cardiogenic shock. The survival benefit of norepinephrine therapy has not been demonstrated in clinical practice, however. This study aimed to explore the relationship between norepinephrine us...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Xin, Wang, Xue, Gao, Yanxia, Walline, Joseph Harold, Yu, Shiyuan, Ge, Zengzheng, Qin, Mubing, Zhu, Huadong, Li, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065839/ https://www.ncbi.nlm.nih.gov/pubmed/35289504 http://dx.doi.org/10.1002/ehf2.13893

Ejemplares similares

CLINICAL PHENOTYPES OF SEPSIS-ASSOCIATED ENCEPHALOPATHY: A RETROSPECTIVE COHORT STUDY
por: Lu, Xin, et al.
Publicado: (2023)

Prognostic Role of Ammonia in Critical Care Patients Without Known Hepatic Disease
por: Zhao, Lina, et al.
Publicado: (2020)

Prehospital norepinephrine administration reduces 30-day mortality among septic shock patients
por: Jouffroy, Romain, et al.
Publicado: (2022)

Effect of Cardiovascular Risk Factors on 30-Day All-Cause Mortality in Cardiogenic Shock
por: Forner, Jan, et al.
Publicado: (2023)

Resources for cardiovascular healthcare associated with 30-day mortality in acute myocardial infarction with cardiogenic shock
por: Ishii, Masanobu, et al.
Publicado: (2021)

Dopamine versus norepinephrine as the first-line vasopressor in the treatment of cardiogenic shock
por: Na, Soo Jin, et al.
Publicado: (2022)

Interleukin-6 is the strongest predictor of 30-day mortality in patients with cardiogenic shock due to myocardial infarction
por: Andrié, René P, et al.
Publicado: (2012)

Comparison of Risk Models in the Prediction of 30-Day Mortality in Acute Myocardial Infarction–Associated Cardiogenic Shock
por: Ranard, Lauren S., et al.
Publicado: (2022)

Dopamine versus norepinephrine in the treatment of cardiogenic shock: A PRISMA-compliant meta-analysis
por: Rui, Qing, et al.
Publicado: (2017)

Effect of Cardiogenic Shock Hospital Volume on Mortality in Patients With Cardiogenic Shock
por: Shaefi, Shahzad, et al.
Publicado: (2015)

Impact of Lactate on 30-Day All-Cause Mortality in Patients with and without Out-of-Hospital Cardiac Arrest Due to Cardiogenic Shock
por: Rusnak, Jonas, et al.
Publicado: (2022)

Prognosis of Patients with Sepsis and Non-Hepatic Hyperammonemia: A Cohort Study
por: Zhao, Lina, et al.
Publicado: (2020)

Hypoalbuminemia is a frequent marker of increased mortality in cardiogenic shock
por: Jäntti, Toni, et al.
Publicado: (2019)

Comparing the Performance of the ABC, AIMS65, GBS, and pRS Scores in Predicting 90-day Mortality Or Rebleeding Among Emergency Department Patients with Acute Upper Gastrointestinal Bleeding: A Prospective Multicenter Study
por: Liu, Shuang, et al.
Publicado: (2021)

The Early Introduction of Extracorporeal Membrane Oxygenation for Postcardiotomy Cardiogenic Shock Does Not Improve 30-Day Mortality Rates in Low-Volume Centers
por: Kunioka, Shingo, et al.
Publicado: (2022)

Effect of norepinephrine dosage on mortality in patients with septic shock
por: Yamamura, Hitoshi, et al.
Publicado: (2018)

INTRA-AORTIC BALLOON PUMP REDUCES 30-DAY MORTALITY IN EARLY-STAGE CARDIOGENIC SHOCK COMPLICATING ACUTE MYOCARDIAL INFARCTION ACCORDING TO SCAI CLASSIFICATION
por: Luo, Da, et al.
Publicado: (2023)

Predictors of 30-day mortality in cancer patients with septic shock
por: Osawa, E, et al.
Publicado: (2015)

Cardiogenic shock /
Publicado: (2002)

Cardiogenic Shock
por: Vahdatpour, Cyrus, et al.
Publicado: (2019)

Circulating levels of microRNA 423‐5p are associated with 90 day mortality in cardiogenic shock
por: Jäntti, Toni, et al.
Publicado: (2018)

Norepinephrine infusion in septic shock
por: Haranath, P. S. R. K.
Publicado: (2008)

Mortality Predictors in COVID-19 Patients with Cardiogenic Shock
por: Brooks, L.C., et al.
Publicado: (2021)

Renal effect of dopamine, norepinephrine, epinephrine, or norepinephrine–dobutamine in septic shock
por: Qiu, HB, et al.
Publicado: (2002)

CARDIOGENIC SHOCK WITH IMIPRAMINE
por: Chaudhury, S., et al.
Publicado: (1990)

Hypothermia in cardiogenic shock
por: van der Pals, Jesper
Publicado: (2012)

Phenotyping Cardiogenic Shock
por: Zweck, Elric, et al.
Publicado: (2021)

ECMO Support in Refractory Cardiogenic Shock: Risk Factors for Mortality
por: Rajsic, Sasa, et al.
Publicado: (2022)

Does Albumin Predict the Risk of Mortality in Patients with Cardiogenic Shock?
por: Schupp, Tobias, et al.
Publicado: (2023)

Norepinephrine for Early Shock Control in Sepsis
por: Tung, Matthew, et al.
Publicado: (2019)

Septic shock and the use of norepinephrine in an intermediate care unit: Mortality and adverse events
por: Hallengren, Mikael, et al.
Publicado: (2017)

Cardiogenic shock teams and centres: a contemporary review of multidisciplinary care for cardiogenic shock
por: Moghaddam, Nima, et al.
Publicado: (2021)

The CSP (Cardiogenic Shock Prognosis) Score: A Tool for Risk Stratification of Cardiogenic Shock
por: Tien, Yu-Tzu, et al.
Publicado: (2022)

Comparison of Norepinephrine and Terlipressin vs Norepinephrine Alone for Management of Septic Shock: Few Concerns
por: Khera, Daisy, et al.
Publicado: (2023)

Statins for Patients with Cardiogenic Shock
por: Champion, Sébastien
Publicado: (2014)

Multidisciplinary teams for cardiogenic shock
por: Vallabhajosyula, Saarwaani, et al.
Publicado: (2019)

Initiation of ivabradine in cardiogenic shock
por: Chiu, Michael H., et al.
Publicado: (2019)

Systems of Care in Cardiogenic Shock
por: Alvarez Villela, Miguel, et al.
Publicado: (2021)

The “Right” Side of Cardiogenic Shock
por: Brailovsky, Yevgeniy, et al.
Publicado: (2020)

Cardiogenic shock: approaching the truth
por: Llaó, Isaac, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_khaes9tk5hal6lfka22iqbmpvm